Novo Nordisk will file oral formulations of its GLP-1 agonist semaglutide for children and adolescents with type 2 diabetes later this year.
FDA approves Regeneron’s hearing loss gene therapy Otarmeni
Regeneron has won the first ever FDA approval for a gene therapy to treat a rare type of inherited hearing loss, and the company plans

